… , so-called minimal residual disease (MRD). These residual cells ultimately are responsible
… on the quantity of residual disease and kinetics of residual leukemia cell division. Sensitive …

… defined with the use of leukemia-specific molecular markers (… levels of leukemia, so-called
minimal residual disease, after … Patients with minimal residual disease in peripheral blood …

… We previously assessed ibrutinib plus venetoclax in patients with relapsed–refractory CLL,
with the duration of therapy defined by the time to undetectable measurable residual disease (…

… as a method of measurable residual disease detection in acute lymphoblastic leukemia. An
… patient with B-cell acute lymphoblastic leukemia (B-ALL). The measurable residual disease (…

… cytometric techniques for the quantitative detection of residual leukemic cells, the presence
of minimal residual disease (MRD) in patients in complete clinical remission has clearly been …

… by morphologic examination was 30.0% ± 17.7% for patients who had residual disease of
0.1% or more in the postinduction 1 sample and 72.1% ± 11.5% for those who had fewer or no …

… ”) residual disease (MRD) in acute myeloid leukemia (AML). Although the perfect MRD test
does not (yet) exist, the strong association between MRD and adverse patient outcomes has …

… In most cases, patients can be treated effectively with chemotherapy … leukemic cells, called
minimal residual disease (MRD; refs. 2–5). MRD can be detected in the majority of patients in (…

… minimal residual disease (MRD) in acute leukemia regardless … mRNA was performed for 9
patients with acute leukemia. In 4 … from leukemia patients at the onset of their disease before …

… Minimal residual disease measurement during or … patients to identify those most likely to
benefit from escalated or additional therapy For patients in complete remission minimal disease …